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Abstract
“Competing Risks” refers to the study of the time to event where there is more
than one type of failure event. The distinct problem can be vital, since not only it can
inform the patients what risks they are facing, but also it helps to select appropriate
treatment for a particular patient. In Chapter 2 we introduce two methods, cause-
specific hazard model and cumulative incidence function, to deal with the competing
risks problem. In Chapter 3, we study the prognosis of different patterns of cancer
recurrences using data from 209 patients who had surgical resection of pancreatic
cancer at the Johns Hopkins Hospital between 1998 and 2007. We analyze different
types of tumor recurrences and death as competing risks. We first apply Cox’s pro-
portional hazard model to analyze the time from surgery to the composite endpoint of
recurrence or death. We then analyze the nonparametric cumulative incidence func-
tion under competing risks setting. The conditional cumulative incidence function
given each event type will be presented to investigate whether the competing risks
have different distribution patterns. Then, the cause-specific hazard model is applied
to evaluate the effect of risk factors on the cause-specific hazards, and the results are
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compared with the conventional survival analysis that ignores the recurrence types.
Finally, we use Cox’s proportional hazard model with time-dependent covariates to
analyze the time from surgery to death. At last, we discuss implications of data
analysis and future research.
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Survival analysis, which is considered a branch of statistics, is widely utilized
in epidemiological and medical studies, especially in cancer research. It deals with
modelling, estimating and testing for time to event data. In survival analysis, sur-
vival time T is time from a defined starting-point to the occurrence of a given event.
For example, in a clinical trial, the survival time may be defined as the time from
the start of certain treatment to diagnosis of disease. When studying disease with
recurrence pattern, the survival time varies with your definition, which may be the
time from receiving the treatment to first diagnosis of recurrence, or the time from
receiving treatment to death. While the recurrence is considered as an endpoint of
survival time in the first scenario, it may be a confounder, effect modifier or mediator
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in the second scenario. Also, in the collection of survival data, censoring and other
sampling constrains, such as left truncation, often arise. Censoring refers to the sce-
nario that we fail to observe the event. It may due to various reasons, such as the end
of study, patients’ dropping out of study, or other reasons for loss to follow-up. In
analyzing survival data, two functions of time are of particular interest: the survival
function and the hazard function. Survival function S(t) is defined as the probability
that a person’s survival time is larger or equal to time t. The hazard function h(t) is
the conditional probability of dying at time t given the subject survived up to that
time. Since the survival function S(t) provides us useful summary information, it is
often desired and common to estimate the survival function S(t) in exploratory data
analysis. The KaplanMeier method (Kaplan and P. [1958]) can be used to estimate
the survival function from the observed survival times with the only assumption that
the censoring mechanism is independent of survival time. Kaplan-Meier method is
based on the idea that the probability of surviving at time t is a product of all survival
rates for each period prior to t. Other than estimating the survival function S(t), we
can also study the hazard function h(t), based on which the Cox proportional hazard
model is formulated (Cox [1972]). Cox proportional hazard model is a semiparamet-
ric model, and it includes two components. One is the unspecified baseline hazard,
and the other parts is the parametric component, where certain covariates of interest
are included, such as age, gender. The model has nice interpretation in terms of
hazard and it is semiparametric. Under the independent censoring condition, based
2
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on proportional hazard model, the likelihood function consists of two parts. The first
likelihood, which is known as “partial likelihood”, only involves the covariates of in-
terest. Thus the computation of the maximum likelihood estimate of those covariates
is manageable, and inference can be made. When the survival time is continuous,
Breslow (Breslow [1974]) gives a ways to estimate the baseline hazard.
Under the conventional survival analysis settings, where only one type of event
can occur during the study, we can use methods described above to estimate survival
function or hazard function. However, more complex circumstance arises during the
study. There may be the study of any failure type in which there is more than one
distinct type of failure but the patient’s eventual failure is attributed to precisely one
of the cause. This kind of situation is referred to as “competing risks”. The dis-
tinct problem can be vital, since it not only informs the patients what risks they are
facing, but also helps to select appropriate treatment for a particular patient. When
we want to study one certain type of failure type under the setting of competing
risks, the previous two conventional methods cannot be applied here, since there may
be dependent censoring occurring. To deal with competing risks problems, the usual
formulation of these problems is in terms of latent failure times corresponding to each
type of failure. We assume that each person may have a potential failure time for
each failure type, which is the latent failure time of certain failure type. Since each
person can only die of one failure type, the survival time or failure time we observe
is the minimum of these latent failure times and the corresponding failure type is the
3
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type of which the person dies (Cox [1959], Moeschberger [1971]). The latent failure
times have two approach of interpretation. Cox [1959] and Moeschberger [1971] de-
fines the failure time for each failure time under competing risks settings to be the
time that would be observed if all other types of failure are removed. However, this
needs strong assumption that certain failure type will operate exactly the same as
under the condition that all other failure types are removed. And usually, the risk of
certain failure type will change if other failure types are removed (Cox [1959], Make-
ham [1874], Cornfield [1957]). The first approach of interpretation, though having a
physical meaning, will not be considered. The second approach the latent failure time
of failure type j is the observed time of failure if the individual fails of type j, while
no physical meaning is attached to unobserved other latent failure times. However,
this approach may lead to lack of physical interpretation of the unobserved latent
failure times and identifiability problems (Prentice et al. [1978]). Therefore, instead
of using latent failure times format, utilizing cause-specific hazard or cumulative in-
cidence function for observed quantities provides us alternative methods to approach
competing risks problems.
In the following chapters, we will first introduce cause-specific hazard and cumula-
tive incidence function, including the definitions, inference and its application to study
competing risks problems. Then we will apply the methods to study the relationship
between survival time and recurrence types among pancreatic cancer patients, and




As mentioned before, “competing risks” refers to the study of any failure type
in which there is more than one distinct type of failure. In the following sections,
we will introduce two popular methods to handle this problem; cause-specific hazard
model (Prentice and Breslow [1978]), estimating cumulative incidence function based
on subditribution hazard (Fine and Gray [1999]).
A statistical model for competing risks data involves the observed quantities
(T, j, z) and the distribution for them, where T is the time to failure or death, and
is a positive random variable; j = 1, . . . ,m refers to the type of failure the patient
has; z is the covariate vector, or the covariates we are interested in. The covariate
vector z may be time-depend, and can be written as z(t). The latent failure times
Y1, Y2, . . . , Ym correspond to each type of failure type j = 1, . . . ,m. The time to
failure or death is T = min(Y1, . . . , Ym) and j = {p|Yp ≤ Yk, k = 1, . . . ,m}. Cj
5
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is the potential censoring time for failure type j = 1, . . . ,m, then potential censor-
ing time C = {Ck|Tk ≤ Tj, j = 1, . . . ,m}. Therefore the observed failure time is
X = min(T,C), and the censoring indicator ∆ = I(T < C). This setting as men-
tioned before lacks physical interpretation and identifiability problem.
2.1 Cause-Specific Hazard
Assume that the failure time T is continuous. The overall hazard function for is
the conditional probability of dying at time t given that a subject survived up to that
time. And the hazard for an individual with the covariate vector z = z(t) is defined
as following,
λ(t; z) = lim
∆t→0
P{t ≤ T < t+ ∆t|T ≥ t; z(t)}/∆t.
Cause-specific hazard functions (Chiang [1968], Altshuler [1970], Holt [1978], Pren-
tice and Breslow [1978]) are defined by
λj(t; z) = lim
∆t→0
P{t ≤ T < t+ ∆t, J = j|T ≥ t; z(t)}/∆t,
for the failure type j = 1, 2, . . . ,m. It simply gives the instantaneous failure rate from
cause j at time t, given the regression vector z(t) (Cox [1972]) and those who survive
time t, in the presence of other failure types. By the previous two definitions, we can
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The overall survival function at time t, which is the probability that a person’s
survival time is larger or equal to time t, can be written as the function of overall
hazard as below,








and the probability for time to failure and cause of failure
fj(t; z
∗) = λj(t : z)F (t; z
∗), (2.2)
where z∗ = z∗(t) denotes {z(u);u ≤ t}, which refers to the history information about
covariates up to time t.
Suppose now there are n study subjects, (ti, ji, δi, zi), where ti is the observed
failure time of subject i, ji is the cause of failure, δi is a censoring indicator, and
z∗i = z
∗
i (t) is a vector-valued regressor for the ith subject. As usual an independent




















The likelihood function is completely specified by the cause-specific hazard func-
tions λj. Rearranging the likelihood factors into a component for each j, the likeli-
hood factor for λj is precisely the same as being obtained by regarding all types of
failure other than type j as being censored at their time of failure. The likelihood
factorization along with standard survival data techniques make it clear that λj, the
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cause-specific hazard function, has the potential to be directly estimated from the
data of the form (t, j, δ, z∗).
2.1.1 Inference on the cause-specific regression co-
efficients
As mentioned before, the jth likelihood factor is precisely the likelihood being
obtained by regarding all other failure types as being censored. This implies the
usual survival data methods for a single failure type can be used for testing and
estimating λj. For example, we can use Cox’s proportional hazard model (Cox [1972,
1975]) in Holt [1978] and Prentice and Breslow [1978] to model effects of regression
covariates in the cause-specific hazard functions as
λj(t; z) = λ0j exp(zβj), j = 1, . . . ,m. (2.4)








where tj(i), i = 1, . . . , dj denotes the dj times of failure of type j, R(tj(i)) is the risk set
prior to tj(i). Standard asymptotic likelihood methods can be applied to the partial
likelihood for the estimate of the β.
Here the assumption that the jth type of failure is independent of other failure
types and censoring. However, no assumption is required concerning the interrelation
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among the other causes of failure. Thus the inference of the coefficients can be made
without introducing strong model assumptions. We note that the interpretation of
the same regression estimate may change under a new set of conditions, for example,
certain types of failure have been removed.
With stronger assumption, that different failure types are independent, a stronger
interpretation can be made about λj. At this time, λj is exactly the hazard function
for cause j given that no other causes are operative. Note that the specific βj can be
estimated using the jth component of the previous partial likelihood function without
restricting other failure types to follow the proportional hazard form.
2.1.2 The study of interrelations among failure types
Failure types j1 and j2 will be said to be related if study subjects at high risk for
a failure type j1 are at the same time at high, or low, risk for a failure type j2. We
can import the definition of time-depend risk-indicator for some failure types which
can establish a relationship to cause-specific hazard functions for other failure types.
For example, j1 indicates death due to lung cancer and j2 refers to stroke. We can
include time-depend covariate as the indicator of j2 in the Cox’s proportional hazard
model for cause-specific hazard for j1. If there is a positive relationship between j1
and j2, then it will indicate individuals at high risk for j1 is simultaneously at high
risk for j2.
9
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2.1.3 Failure rate estimation following cause re-
moval
Another problem we will address in competing risks is to estimate the failure rates
for certain causes given the removal of some or all other causes. This kind of problem
is not in general well defined until the mechanism for cause removal is clearly specified,
and it is necessary to explore detailed knowledge of the biological mechanism giving
rise to failures.
Chiang (Chiang [1968]) asserts that a very strong assumption, that the instanta-
neous failure rate for cause j under actual conditions, with all m causes operative, is
identical to that under new condition where only cause j presents, is needed when you
want to base the probability statements for cause j considering it’s the only failure
type on cause-specific hazard function λj.
2.2 Cumulative Incident Function
In the presence of competing risks, the cumulative incidence function is the prob-







CHAPTER 2. COMPETING RISKS MODELS
Then a nonparametric estimator can be obtained by first calculating the Kaplan-
Meier estimate of the overall survival function Ŝ(t), and then at the observed time ti,
where δi = 1 and Ji = j.
Besides the nonparametric estimator, we introduce a semi-parametric estimator
for CIF by Fine and Gray [1999]. To simple the procedure, our interest here is to
model the CIF for failure type 1,
F1(t; z) = Pr(T ≤ t; J = 1|z). (2.7)
Instead of estimating CIF directly, we consider the class of semiparametric trans-
formation models (Cheng et al. [1995], Cox [1972], Cuzick [1988], Dabrowska and
Doksum [1988], Fine et al. [1998], Murphy et al. [1997]). The transformation formula
is
g{F1(t;Z)} = h0(t) + ZTβ0 (2.8)
where h0 is a completely unspecified, invertible, and monotone increasing function.
On the scale of g, the regression coefficients are a measure of distance from the baseline
marginal probability function g−1{h0(t)}.
The first step is to try g = log{− log(1 − u)} (Fine and Gray [1999]), since it is
corresponding to the popular hazard model. However, we should notice the hazard
here is not the usual cause-specific hazard and define it as subdistribution hazard
( Gray [1988]);




Pr{t ≤ T ≤ t+ ∆, J = 1 | T ≥ t ∪ (T ≤ t ∩ J 6= 1), z}, (2.9)
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then we can get:
λ∗1(t; z) = {dF1(t; z)/dt}/{1− F1(t; z)} (2.10)
= −d log{1− F1(t; z)}dt. (2.11)
We can think of λ∗1 as the hazard function for improper random variable T
∗ =
I(J = 1)× T + I(J 6= 1)×∞. T ∗ has the distribution function equal to F1(t; z). In
this scenario, failure from other causes in unobservable, and the estimation of overall
survival is equal to the estimation of the subdistribution for individuals who will even-
tually experience the event of interest. However, in general competing-risks setting,
failure from other causes are observable. Therefore, interpretation of g-transformation
model for CIF is problematic if viewed in terms of the corresponding hazard function.
Let












Thus the regression coefficients and baseline hazard from the Cox transformation
model for F1 have a straightforward interpretation that does not depend on the prob-
lematic structure of the subdistribution hazard.
In the following sections, we will show that a modified partial likelihood method
can be apply on the subdistribution hazards with complete and censoring complete
data.
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2.2.1 Complete data
This procedure, which can be viewed as a modification of partial likelihood, yields
estimates for the regression parameters that are consistent and asymptotically normal
(Fine and Gray [1999]). A version of Breslow’s estimator (Breslow [1974]) provides a
consistent estimate for Λ∗10(t) =
∫ t
0
λ∗10(s)ds that is equivalent to a mean 0 Gaussian
process.
We define the risk set at the time of failure for ith individual,
Ri = {k : (Tk ≥ Ti) ∪ (Tk ≤ Ti ∩ jk 6= 1)}.
This includes two groups: those who have survived at time t and those who have
failed from other causes before time t. It leads to the proper partial likelihood for the











Then we can get the maximum likelihood estimate for β and derive the asymp-
totic normal distribution, which inherited from the ordinary Cox proportional hazard
model.
2.2.2 Censoring complete data
In some designed clinical trials, censoring only results from administrative loss-to-
follow up, which means the patients have not failed by the time the data are analysed.
13
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Under this condition, the potential censoring time is always observed. We call these
data censoring complete.
We then redefine the risk set at the time of failure for ith individual (Fine and
Gray [1999]):
Ri = {k : (Ck ∧ Tk ≥ Ti) ∪ (Tk ≤ Ti ∩ jk 6= 1 ∩ Ck ≥ Ti)}. (2.15)
In this setting, an individual with J 6= 1 is still “at risk” for fail from cause of interest
until censoring time C. If (T, J) and C are conditionally independent given covari-
ates, then the “crude” subdistribution hazard function with censoring-complete data,
λ1∗{t; z}, is equivalent to the “net” subdistribution hazard function with complete
data, λ∗1{t; z} (Fine and Gray [1999]).
Using the censoring-complete risk set setting, the partial likelihood principle can
again be applied to the model for λ∗1{t; z}. And the asymptotic results for the




A Pancreatic Cancer Study
3.1 Background
Pancreatic cancer is a malignant neoplasm originating from transformed cells aris-
ing in tissues forming the pancreas. The most common type of pancreatic cancer, con-
stituting about 95% of these tumors, is adenocarcinoma appearing within the exocrine
component of the pancreas. This kind of tumor exhibites glandular architecture on
microscopy. The signs and symptoms, which eventually lead to the diagnosis depend
on many factors, such as the location, the size, and the tissue type of the tumor.
Other information related to physiological abnormality, including abdominal pain,
lower back pain, jaundice, which may be caused if the tumor compresses the bile
duct, unexplained weight loss, and digestive problems, are also considered.
According to World Health Organization, pancreatic cancer is the fourth most
15
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common cause of cancer-related deaths in the United States and the twelfth most
common cause of cancer-related deaths worldwide. Pancreatic cancer has an ex-
tremely poor prognosis: for all stages combined, the one-year and five-year relative
survival rates are just 25% and 6% respectively; from American Cancer Society, for
local disease the five-year survival is approximately 15% while the median survival for
locally advanced and for metastatic disease, accounting for over 80% of individuals
from National Cancer Institute, is about 10 and 6 months respectively. Individuals
vary from each other. However some are diagnosed when they are already in stage IV,
therefore only have a few days or weeks to live. Others, who have slower progression,
may live a couple of years even if they cannot have the surgery. Men are 30% more
likely to get pancreatic cancer than women.
Family history may be considered as a risk factor, since 5-10% of pancreatic cancer
patients have a family history of pancreatic cancer (Ghaneh et al. [2007]). The risk
of developing pancreatic cancer increases with age. Most cases occur after age 60,
while cases before age 40 are rare. Smoking has a risk ratio of 1.74 with respect to
pancreatic cancer; a decade of nonsmoking after heavy smoking is associated with a
risk ratio of 1.2 (Iodice et al. [2008]). Obesity is also considered as a risk factor for
pancreatic cancer (Society [2008]).
However, the prognosis of different patterns of recurrence, particularly in lung,
for pancreatic cancer patients who had had surgery has not been well studied. The
relationship between survival time and recurrence patterns may help us predict the
16
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prognosis in the future and assign appropriate treatment to the patient given their
recurrence pattern.
Here we have three recurrence types, one is having recurrence in lung before death,
denoted as recurrence-in-lung; one is having recurrence in sites other than lung
before death, denoted as recurrence-in-other-sites; and the third is not having
recurrence before death, denoted as no-recurrence.
3.2 Summary of Baseline Covariates
The medical records of 209 patients who had surgical resection of pancreatic cancer
and had postoperative follow-up primarily at the Johns Hopkins Hospital between
1998 and 2007 were retrospectively reviewed. Among the 209 patients, 13.4% had
recurrence only in lung; about 70% of the patients had recurrence in sites other
than lung; 16.74% of the patients did not have metastasis. We perform survival
analysis on two types of survival outcomes. One is the time from the surgery to the
date of first diagnosis of recurrence. However, the diagnosis of lung recurrence was
often delayed. Therefore, the recurrence time we observed here might not be the true
recurrence time. The other time period is the time from surgery to death or censoring.
Age, gender, cancer staging, margins, lymph node, grading differentiation, vascular
invasion, perineural invasion, therapy type are also provided in the data set. The
summary information about these covariates are shown below in Table 1. The mean
17
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age of the whole data set is 64.23, with standard deviation 10.94. The three subgroups,
recurrence-in-lung, recurrence-in-other-sites and no-recurrence, have similar mean in
age. However, the standard deviation of it for the patients with recurrence in lung
is smaller, which means age in this subgroup is more concentrated around the mean.
Given gender, the difference between the number of female and that of male is quite
small in the whole data set, the-recurrence-lung subgroup and recurrence-in-other-
sites subgroup. However, the number of male in no-recurrence subgroup is almost
twice as large as that of female in this group.
Cancer staging is the process of determining the extent to which a cancer has
developed by spreading. The larger the cancer staging is, the poor the prognosis. In
Table 3.1, majority, above 90%, of the patients in the study in stage II, which is the
moderate prognosis in cancer staging, and only 17 people are either in stage I or III.
The three subgroups share similar patterns.
Margin refers to the edge or border of the tissue removed in cancer surgery. The
margin is described as negative or clean when the pathologist finds no cancer cells at
the edge of the tissue, suggesting that all of the cancer has been removed. The margin
is described as positive or involved when the pathologist finds cancer cells at the edge
of the tissue, suggesting that all of the cancer has not been removed. Usually positive
margin means better prognosis. In Table 3.1, the number of patients with positive
margins is close to that of patients with negative margins in the whole data set, which
also happens in the recurrence-in-lung and no-recurrence subgroups. However, in the
18
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recurrence-in-other-sites subgroup, 81 patients are with negative margins while only
65 with positive margins. We may want to consider this difference in our later model.
Tumor grade is a way of classifying tumors based on certain features of their cells.
The grade of a tumor is directly linked to prognosis. It is to check how much the
cancer cells look like normal cells: the more the cancer cells look like normal cells, the
lower the tumor grade tends to be. It also consider how many of the cancer cells are in
the process of dividing: the fewer cancer cells that are in the process of dividing, the
more likely it is that the tumor is slow-growing slowly and the lower the tumor grade
tends to be. Well-differentiated means the tumor cells look the most like normal tissue
and are slow-growing, moderate-differentiated means the tumor cells fall somewhere
in between Grade 1 and Grade 3, and poorly-differentiated means the tumor cells look
very abnormal and are fast-growing. In Table 3.1, in the whole data set and also in
three subgroups, most patients were poorly or moderate-differentiated. However, in
recurrence-in-lung patients, 75% of those are moderate-differentiated, while 50.68%
of the recurrence-in-other-sites patients and 37.14% of the no-recurrence patients are
moderate-differentiated.
Lymph nodes refers to the indicator of whether the cancer has spread to lymph
nodes. The prognosis is poorer if lymph node is positive, since the cancer cell can
travel to the rest of the body by the lymph system. In Table 3.1, among all the
patients, 86.12% are positive in lymph nodes, 92.86% in recurrence-in-lung, 85.62%
in recurrence-in-other-sites, and 82.86% in no-recurrence. Carrying out chi-square
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test, we find out the p-value is significant, which indicates the distributions of lymph
node in four groups are different. With further examining, the distribution in the
recurrence-in-other-sites is different from those of the other three groups.
Vascular invasion is the indicators that we have that cells have a tendency to
go into the vascular system and to spread to the rest of the body. Most of the
patients without information about vascular invasion were in subgroup of patients
with recurrence-in sites other than lung. Perineural invasion, abbreviated PNI, refers
to cancer spreading to the space surrounding a nerve. In Table 3.1, among all patients,
recurrence-in-other-sites and no-recurrence, more than 90% are “Yes”, while 85.71%
in recurrence-in-lung are “Yes”.
Therapy information provides us which therapy the patient had, radiotherapy,
chemotherapy or both. In Table 3.1, in no-recurrence subgroup, about 40% of the
patients lose information about the therapy. In other two subgroups, at least 76%
of the patients have received the therapy. The p-values of the two therapies are
significant, and this may due to the fact that about 40% people in the no-recurrence
group do not have information about it, and the percentile is much higher than the
other three groups.
20
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3.3 Cox’s Proportional Hazard Model With-
out Recurrence Type Information
3.3.1 Time from surgery to composite endpoint of
recurrence and death
The first outcome of interest is time from surgery to composite endpoint, which
includes recurrence only in lung, recurrence in sites other than lung and death without
having recurrence. Conventional Cox’s model with the main effects as covariates is
considered here to discover the main effects that may effect the risk. The result
is shown in Table 3.2. We can see both the linear and quadratic term of age have
significant p-values, 0.03. From the estimate of coefficients, those youngest and oldest
patients in the data tend to have a greater risk of the composite event, while the
patients with age from 55 to 75 tend to have lower risk. Receiving radiation therapy
is found to decrease the risk by 40%. Later, we will compare the coefficients with
those we get from cause-specific hazard model in Section 3.4.2.
3.3.2 Time from surgery to death
In this section, we analyze time from surgery to death, but ignore the recurrence
types here. The conventional Coxs model with same set of covariates is considered
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here. The result is shown in Table 3.3. We can see the linear and quadratic term
of age, gender and perneural invasion have significant p-values. Radiation therapy
does not show significance here, different from that in Table 3.2. Age seems to follow
similar pattern as in Section 3.3.1. The risk of death for those having perneural
invasion is about three times as much as that for those not having. In Section 3.5.2,
we will compare the results with the coefficients of main effects in the cause-specific
hazard model.
3.4 Survival Analysis for Time from Surgery
to Recurrence
In this section, we mainly deals with time from surgery to the time when the
recurrence was first diagnosed or death without recurrence. We want to see how
different baseline characteristics influence the risk of different recurrence types, and
how the time from surgery to the recurrence first diagnosed varies across different
recurrence types.
3.4.1 Cumulative incidence function
We estimate cumulative incidence function to discover whether recurrence type
influences the survival outcome, the time from surgery to recurrence or death if there
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was no recurrence. The cumulative incidence curve estimate was from the cmprsks
cuminc() function (Gray [1988]). We can see from Figure 3.1 that the probability
that patients were first diagnosed of recurrence in sites other than lung before time
t increases much more rapidly when t goes from 0 to 12, reaches about 0.45 at the
end of first year, and then the slope decreases. After 40 months, the line of the
cumulative incidence function for recurrence in other sites becomes quite stable and
is close to 0.70. The probability that patients were first diagnosed of recurrence only
in lung before t increases most slowly among the three risk types when t is in [0, 40].
When t is 40, there is a cross-over between the line of recurrence-in-lung subgroup and
no-recurrence group. We realize that few people survived very long in no-recurrence
subgroup, and it may cause the cross-over here. Finally, the cumulative incident
function of recurrence-in-lung and that of no-recurrence both go to about 0.15.
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Figure 3.1: The nonparametric estimate of cumulative incidence function and 95%
confidence intervals.
Since most patients in this study are in recurrence-in-other-sites subgroup (69.86%),
the difference in cumulative incidence functions is larger because of prevalence rates
of the failure events. Then we condition on that a failure type occurred during the
study period to see if the conditional cumulative incidence functions for the three
types are significantly different. The result is in Figure 3.2. The solid lines are
the estimate of conditional cumulative incidence functions, and the dashed lines are
the 95% confidence intervals of the estimate using the bootstrap resampling method.
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From Figure 3.2, the conditional subdistribution of no-recurrence group increases
most rapidly within the first 12 months, followed by that of recurrence-in-other-sites
subgroup. Then slope of the curve with regards to no-recurrence, decreases as most
patients died in this subgroup. The cumulative incidence curve of recurrence-in-lung
subgroup increases most slowly within first 40 months. Since the sample sizes vary in
different subgroups, the estimate of the cumulative incidence curve of the recurrence-
in-other-sites subgroup, with the largest sample size, has the most narrow confidence
interval, while the widths of the confidence intervals of other two subgroups are rela-
tively large.
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Figure 3.2: Estimated conditional cumulative incidence functions and 95% bootstrap
confidence intervals.
3.4.2 Cause-specific hazard
We have reviewed the methods of cause-specific methods. From Section 2.1, we
know the jth likelihood factor in the full likelihood function, is precisely the likelihood
being obtained by regarding all other failure types as being censored. The usual
survival data methods for a single failure type can be used for testing and estimating
λj. Here we use Cox’s proportional hazard model for
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λj(t; z) = λ0j exp(zβj), j = 1, . . . ,m. (3.1)
3.4.2.1 With only main effects
First we only include main effects in each of the cause-specific hazard model, same
covariates with the model in Section 3.3.1. In Table 3.3, none of the main effects
in the cause-specific hazard for no-recurrence and recurrence-in-lung subgroups are
significant. And only positive margin in the model for recurrence-in-lung subgroup
has a p-value of 0.06, close to 0.05. This may due to the small sample size of these
two subgroups. We note that the variances of stage, lymph node and chemo therapy
in the recurrence-in-lung cause-specific hazard model are large, and so are the ranges
of their 95% confidence intervals. This may due to small sample size , and also the
unequal distribution of patients in each category of the covariate. For example, only
one of the 28 patients in recurrence-in-lung subgroup is in Stage I, while all the other
are in Stage II (Table 3.2). Similar thing happens to lymph node and radiation in the
no-recurrence cause-specific hazard model too. However, in this model, the perneural
invasion and stage has extreme large estimate and variance. When we check the data,
we find out that only two people in this subgroup did not have perneural invasion,
and they lived up to 133 and 129 months. Regarding the cancer staging information,
only one person in no-recurrence subgroup was in Stage I, who lived up 129 months,
while two people in the same group was in Stage III, and they lived 3.38 and 1.15
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months respectively, both very short. Since these patients are sparse in the sample, it
is not reasonable to include perneural invasion and stage in the model. While looking
at the cause-specific hazard model for recurrence-in-other-sites, other than the three
significant main effects in Table 3.2, we find out the gender is also a significant main
effect.
3.4.2.2 With some of the main effects and interaction terms
By exploring different models, we fit proportional hazard model for the cause-
specific hazard models for three recurrence types in Table 3.5.
In the recurrence-in-lung subgroup, Table 3.5, the positive margin and the in-
teraction tern of the positive margin and gender have significant p-values, that are
0.006 and 0.03 respectively. Among the females who had recurrence in lung, the
cause-specific hazard rate of those with positive margin is about 7 times greater than
that of those with negative margin indicator. Among the males who had recurrence
in lung, the cause-specific hazard rate of those with positive margins is 1.2 times as
large as that of those with negative margins. In the recurrence-in-lung subgroup, the
margin indicator influences females much more than males. Age, which is always an
important characteristic in cancer study, does not seem to play an important role
here, the coefficient associated with it is 1.03 with an insignificant p-value of 0.19.
The appearance of cancer cells in lymph nodes increases the cause-specific hazard
by 2.82 times, which is consistent with empirical facts. However its 95% confidence
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interval is [0.63, 12.74] and standard deviation is large, the accuracy of the estimate
can not be assured. The similar circumstance happens to grade differentiation, vas-
cular invasion, perineural invasion, chemo therapy and radiation therapy. The effect
of these baseline characteristics are not certain, and more data are needed.
The Table 3.5 shows the results from estimate of the cause-specific hazard for
recurrence-in-other-sites. Among all the baseline characteristics, age, gender grade
differentiation, radiation therapy and interaction term of age and gender have sig-
nificant p-values. Among patients having recurrence in sites other than lung, age
follows the same pattern as that in Table 3.4. However, the effect of age in females
is sightly different from that in males. The youngest and oldest patients are at more
risk in this subgroup. The risks of females and males at the same age are also very
different: the cause-specific hazard rate of the males is 25 times as large as that of
the females. Besides, the hazard of the patients who were poorly-differentiated in
recurrence-in-other-sites subgroup at time t is 1.86 times greater than that from the
moderate-differentiated patients in the same subgroup. We also notice radiation ther-
apy has a significant p-value while chemo therapy does not. The risk of the patients
who had radiation therapy decreases by 87% comparing to those who did not. How-
ever, 76.71% of the patients in recurrence-in-other-sites received radiation therapy,
and there may be the possibility that those, not receiving radiation therapy, died too
early to receive therapy. Further tests need to be carried out to see if radiation ther-
apy really helps to reduce risk. The baseline characteristic vascular invasion, though
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its p-value is not significant, has a 95% confidence interval of [0.98, 2.19], the lower
end of which is very close to 1, it is reasonable to consider that it does have impact
on the cause-specific hazard, and it increases the risk by 0.46 if the vascular invasion
appears.
Among patients who had no recurrence, none of the baseline characteristics in our
model are significant (see Table 3.5). This may result from the fact that almost 40%
of the patients in this 35-patient subgroup had missing values in radiation therapy.
The grade differentiation indicator has the smallest p-value of 0.07. When looking at
its 95% confidence interval [0.09, 1.09], the upper end of the interval is very close to 1.
The differentiated grade of the cancer cell may have effect on the cause-specific hazard
for patients not having recurrence. The risk of the patients poorly-differentiated in
no-recurrence subgroup is 0.39 times greater than that of the moderate-differentiated
patients in the same subgroup. The 95% intervals of lymph node and radiation
therapy have large range, which may due to small sample size of this subgroup.
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3.5 Survival Analysis for Time from Surgery
to Death
In this section, we study time from surgery to death. The three types of recurrence
patterns are defined same as in the previous section. Similar procedure is carried out
as previous section.
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3.5.1 Cumulative incidence function
Instead of using conventional survival analysis, we analyze the problem by regard-
ing it as competing risks problem and tried to estimate cumulative incidence functions
of the three subgroups. Based on the same methods as previous section, in Figure
3.3, the probability that patients not having recurrence before time t increases most
rapidly when t is less than half a year, and has the value 0.08 at the end of the sixth
month. Then its slope decreases. After 6 months, the cumulative incidence curve for
recurrence in other sites increases the fastest. The probability of death for patients
first diagnosed of recurrence only in lung before time point t increases most slowly
among the three risk types. Finally, since recurrence-in-lung and no-recurrence sub-
groups have similar sample size, the cumulative incidence functions of them both go
to about 0.1.
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Figure 3.3: The nonparametric estimate of cumulative incidence function and 95%
confidence intervals.
Since most patients in this study are in recurrence-in-other-sites subgroup (69.86%),
the difference in cumulative incidence functions is larger due to prevalence rates of
the failure events. Therefore, we condition on that a recurrence type occurred during
the study period to see if the conditional cumulative incidence functions for three
recurrence types are significantly different. The result is in Figure 3.4. The solid
lines are the estimate of conditional cumulative incidence functions, and the dashed
lines are the 95% confidence intervals of the estimate using the bootstrap resampling
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method. From Figure 3.4, the conditional subdistribution of no-recurrence group
increases most rapidly within the first 20 months, followed by that of recurrence-in-
other-sites subgroup. Then, increase rate of the curve, with regards to patients not
having recurrence, becomes slower as most patients died in this subgroup. Compar-
ing to Figure 3.2 in Section 3.4.1, the difference between rate of cumulative incidence
curve of no-recurrence subgroup and that of recurrence-in-other-sites becomes larger,
since those who had recurrence in other sites were alive for a while after recurrence.
The cumulative incidence curve of recurrence-in-lung subgroup increases most slowly.
And because of difference in sample size in three subgroups, the estimate of the
cumulative incidence curve of the recurrence-in-other-sites subgroup, which has the
largest sample size, has the most narrow confidence interval, while the widths of the
confidence intervals of other two subgroups are relatively large.
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Figure 3.4: Estimated conditional cumulative incidence functions and 95% bootstrap
confidence intervals.
3.5.2 Cause-specific hazard
3.5.2.1 With only main effects
First we only include main effects in each of the cause-specific hazard model. None
of the main effects in the cause-specific hazard for no-recurrence and recurrence-in-
lung subgroups are significant. And only positive margin in the model for recurrence-
in-lung subgroup has a p-value of 0.08, close to 0.05. This may due to the small
sample size of these two subgroups. We note that the main effects: lymph node,
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perneural invasion and chemo therapy, in the recurrence-in-lung cause-specific hazard
model have large variance, and the ranges of their 95% confidence intervals are large.
Besides the small sample size problem, the unequal distribution of patients in each
category of the main effect may also be a reason. For example, only two of the 28
patients in recurrence-in-lung subgroup did not have cancer cell appearing at lymph
node, while all the other had. Similar thing happens to lymph node and radiation in
the no-recurrence cause-specific hazard model too. However, in this model, estimate
of coefficient of stage is really large, which is 17.02, and so is the variance. When
we check the data, we find out that only one person in this subgroup was in stage
I, and lived up to 142 months, while all other people in this subgroup were in stage
II. Because of this sparsity problem, it is not reasonable to include stage in this
cause-specific hazard model. While looking at the cause-specific hazard model for
recurrence-in-other-sites, perneural invasion does show significance as it does in Table
3.6, but it is 0.07, close to 0.05.
3.5.2.2 With some of the main effects and interaction terms
Then we fit proportional hazard model for the cause-specific hazard models for
three recurrence types in Table 3.7.
In the recurrence-in-lung subgroup, Table 3.7, the positive margin indicator and
the interaction tern of the margin indicator and gender have significant p-values, that
are 0.01 and 0.04 respectively. It agrees with the results in Table 3.5. Among the
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females who had recurrence in lung, the cause-specific hazard rate of those whose
margins were positive is 5.7 times greater than that of those with negative margin
indicator, which is a little smaller than that in Table 3.5. Among the males who had
recurrence in lung, the cause-specific hazard rate of those with positive margins is
1.02 times as large as that of those with negative margins, which indicates the margin
indicator has less effect on males. Age, which is always an important characteristic
in cancer study, does not seem to play a key role here, the coefficient associated
with it is 1.01 with an insignificant p-value of 0.57, however, this may due to the
small sample size. Though the coefficient of lymph nodes is 5.98, the 95% confidence
interval of it is [0.78, 46.08], which means the accuracy of the estimate can not be
assured. The similar circumstance happens to grade differentiation, vascular invasion,
perineural invasion, chemo therapy and radiation therapy. The effect of these baseline
characteristics on cause-specific hazard are not certain, and more data are needed.
The Table 3.7 shows the results from estimate of the cause-specific hazard for
recurrence-in-other-sites. Among all the baseline characteristics, age, age2, gender,
vascular invasion and the interaction term of age and gender have significant p-values,
which are different from results in Table 3.5, where grade differentiation and radia-
tion therapy are significant. Though the interaction term of age and gender has a
significant p-value, the estimate coefficient is 1.05, which indicates the risks of females
and males at the same age do vary much from each other. Among patients having
recurrence in sites other than lung, the coefficients of age and its quadratic term are
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close to those in Table 3.5. The effect of age in this subgroup regarding to different
endpoints, recurrence and death, is similar. The risk of the patients who had vascular
invasion in recurrence-in-other-sites subgroup at time t is 0.52 times greater than that
of patients not having it in the same subgroup, with other covariates held. It agrees
with the empirical fact that arise of vascular invasion often means poor prognosis.
Among patients who had no recurrence, Table 3.7, none of the baseline character-
istics in our model are significant, which agreed with the results in Table 3.5. This
may due to the same reason that almost 40% of the patients in this 35-patient sub-
group had missing values in radiation therapy. Age has the smallest p-value of 0.06,
and when looking at its 95% confidence interval [0.36, 1.02], the upper end of the
interval is very close to 1. Therefore, age may have effect on the risk of patients not
having recurrence before death. Similar thing happens to age2. Perneural invasion,
lymph node and radiation have large standard deviations, and this may due to small
sample size of this subgroup.
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3.5.3 Cox’s proportional hazard model with time-
dependent covariates
In this subsection, instead of using competing risks models, we set no-recurrence
as our reference group, import two time-depend risk indicators for recurrence-in-lung
and recurrence-in-other sites, and then apply Cox’s proportional hazard model to
time from surgery to death or censoring including all the baseline characteristics.
The results are in Table 3.8. The estimate of coefficient related to time-depend
risk-indicator of recurrence-in-lung is 0.57 with a p-value of 0.04, which means that
the hazard of those who discovered lung recurrence decreases by 43% comparing to
those who did not have recurrence in lung, given that all other covariates are the
same. The estimate of coefficient related to time-depend risk-indicator of recurrence-
in-other-sites is 1.82 with a p-value of 0.002. Then the hazard of those who had
recurrence in sites other than lung increases by 82% comparing to that of those who
did not have, with all other covariates held. We also consider interaction terms of
gender and time-depend risk indicator. The p-values of these interaction terms are not
significant, though the estimate values themselves indicates the risk of males having
recurrence event increases comparing to those not have recurrence. The quadratic
term of age is included in the model, since we discover the youngest patients and
oldest patients in the study are likely to die early, while patients from 55 to 75
are most likely to live longer. Among baseline characteristics, margin indicator and
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perineural invasion indicator have significant p-values of 0.01 and 0.001 respectively.
The hazard of the patients with positive margins increases by 42% comparing to that
of patients with negative margins, when holding all other covariates in the model.
Also, the patients having perinueral invasion have hazard 2.77 times as large as those
without perineural invasion, with the other covariates held.
Furthermore, we study whether the time to have recurrence in lung influence the
risk of the patient. We includes two time-depend risk indicators related to recurrence
in lung: one indicates whether the patient had diagnosed of recurrence in lung within
6 months after the surgery, and the other indicates whether the diagnosis occurred
longer than 6 months after surgery. In the Table: 3.9. recurrence in lung occurring
within 6 months after surgery increases the risk by 11%, while recurrence in lung
occurring longer than 6 months after surgery decreases the risk by 55%. However,
neither of the p-values are significant, it may be the reason that the sample size of
patients who only had recurrence in lung is too small. We may want to study more
patients who had recurrence only in lung to see if this difference actually exists.
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Table 3.1: Summary Table of The Baseline Characteristics
covariates whoel.data.set recurrence.in.lung recurrence.in.other.sites no.recurrence p-value
number of patients(%) 209(100) 28(13.40) 146(69.86) 35(16.74)
Age(SD) 64.23(10.94) 65.25(8.50) 63.38(11.13) 66.97(11.60)
gender 0.2512
Male(%) 100(47.85) 15(53.57) 71(48.63) 23(65.71)
Female(%) 109(52.15) 13(46.43) 75(51.37) 12(34.29)
cancer staging 0.5706
I(%) 11(5.26) 1(3.57) 9(6.16) 1(2.86)
II(%) 191(91.39) 27(96.43) 133(91.1) 31(88.57)
III(%) 6(2.87) 0(0) 4(2.74) 2(5.71)
Unknown(%) 1(0.48) 0(0) 0(0) 1(2.86)
margins 0.5266
Postive(%) 100(47.85) 15(53.57) 65(44.52) 20(57.14)
Negative(%) 109(52.15) 13(46.43) 81(55.48) 15(42.86)
Lymph Nodes 0.001
Yes(%) 180(86.12) 26(92.86) 125(85.62) 29(82.86)
No(%) 29(13.88) 2(7.14) 21(14.38) 6(17.14)
Grade Differentiation 0.06209
Poor(%) 108(51.67) 7(25) 68(46.58) 21(60)
Moderate(%) 94(44.98) 21(75) 74(50.68) 13(37.14)
Well(%) 3(1.44) 0(0) 4(2.74) 0(0)
Unknown(%) 4(1.91) 0(0) 0(0) 1(2.86)
Vascular Invasion 0.5199
Yes(%) 103(49.28) 13(46.43) 71(48.63) 19(54.29)
No(%) 81(38.76) 13(46.43) 53(36.3) 15(42.86)
Unknown(%) 25(11.96) 2(7.14) 22(15.07) 1(2.86)
Perineural Invasion 0.9338
Yes(%) 192(91.87) 24(85.71) 136(93.15) 32(91.43)
No(%) 12(5.74) 3(10.71) 7(4.79) 2(5.71)
Unknown(%) 5(2.39) 1(3.57) 3(2.05) 1(2.86)
Radiation Therapy 0.001286
Yes(%) 156(74.64) 24(85.71) 112(76.71) 20(57.14)
No(%) 25(11.96) 3(10.71) 20(13.7) 2(5.71)
Unkown(%) 28(13.4) 1(3.57) 14(9.59) 13(37.14)
Chemo Therapy 3.098e−06
Yes(%) 165(78.95) 26(92.86) 120(82.19) 19(54.29)
No(%) 20(9.57) 1(3.57) 17(11.64) 2(5.71)
Unkown(%) 24(11.48) 1(3.57) 9(6.16) 14(40)
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Table 3.2: Proportional Hazard Model of Time from Surgery to Composite Endpoint
with Only Main Effects
coef exp(coef) se(coef) p lower .95 upper .95
age -0.20 0.82 0.09 0.03 0.68 0.98
age × age 0.002 1.002 0.0007 0.03 1.0002 1.0031
gender -0.33 0.72 0.18 0.06 0.50 1.02
positive margin 0.30 1.34 0.18 0.10 0.94 1.91
lymph node 0.45 1.57 0.30 0.13 0.88 2.81
grade -0.23 0.79 0.17 0.17 0.57 1.11
vascular invasion 0.22 1.24 0.17 0.21 0.88 1.75
perneural invasion 0.66 1.94 0.37 0.08 0.93 4.03
chemo -0.29 0.75 0.43 0.50 0.32 1.74
radiation -0.88 0.41 0.39 0.02 0.19 0.88
stage 0.02 1.02 0.48 0.96 0.40 2.61
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Table 3.3: Proportional Hazard Model of Time from Surgery to Death with Only
Main Effects, Ignoring the Recurrence Types
coef exp(coef) se(coef) p lower .95 upper .95
age -0.25 0.78 0.09 0.01 0.65 0.94
age × age 0.0002 1.00 0.0008 0.01 1.0005 1.0035
gender -0.37 0.69 0.19 0.05 0.48 1.0006
positive margin 0.29 1.34 0.18 0.10 0.94 1.91
lymph node 0.43 1.53 0.30 0.16 0.85 2.77
grade -0.05 0.95 0.17 0.75 0.68 1.32
vascular invasion 0.16 1.17 0.18 0.38 0.82 1.66
perneural invasion 1.11 3.04 0.42 0.01 1.33 6.95
chemo -0.14 0.87 0.43 0.73 0.37 2.00
radiation -0.26 0.77 0.39 0.51 0.36 1.67
stage -0.03 0.97 0.50 0.95 0.36 2.58
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Table 3.4: Cause-Specific Hazard of Time from Surgery to Recurrence With Only
Main Effects
coef exp(coef) se(coef) p lower .95 upper .95
Recurrence-in-lung
age 0.08 1.09 0.31 0.79 0.59 2.01
age × age -0.0004 1.00 0.0002 0.87 0.99 1.0004
gender -0.25 0.78 0.45 0.58 0.32 1.88
positive margin 0.85 2.34 0.45 0.06 0.96 5.71
lymph node 1.01 2.75 1.07 0.35 0.34 22.57
grade 0.58 1.79 0.44 0.19 0.75 4.26
vascular invasion 0.07 1.07 0.41 0.87 0.48 2.37
perneural invasion 0.45 1.57 0.70 0.52 0.40 6.13
chemo 1.26 3.53 1.44 0.38 0.21 59.71
radiation -1.08 0.34 1.06 0.31 0.04 2.70
stage -0.15 0.86 1.47 0.92 0.05 15.14
Recurrence-in-other-sites
age -0.23 0.79 0.10 0.02 0.65 0.97
age × age 0.00 1.00 0.00 0.03 1.00 1.00
gender -0.43 0.65 0.21 0.04 0.44 0.98
positive margin 0.18 1.19 0.21 0.39 0.80 1.78
lymph node 0.35 1.42 0.33 0.29 0.74 2.71
grade -0.34 0.71 0.19 0.08 0.48 1.04
vascular invasion 0.29 1.34 0.20 0.15 0.90 1.99
perneural invasion 0.64 1.89 0.46 0.16 0.78 4.62
chemo -0.34 0.71 0.47 0.46 0.28 1.77
radiation -0.93 0.39 0.42 0.03 0.17 0.90
stage -0.01 0.99 0.52 0.98 0.35 2.75
No-recurrence
age -0.27 0.77 0.32 0.40 0.41 1.43
age × age 0.00 1.00 0.00 0.34 1.00 1.01
gender 0.33 1.39 0.74 0.66 0.32 5.92
positive margin 0.42 1.52 0.67 0.54 0.41 5.68
lymph node 0.84 2.31 0.99 0.40 0.33 16.06
grade -0.83 0.44 0.66 0.21 0.12 1.60
vascular invasion 0.07 1.07 0.66 0.91 0.29 3.92
perneural invasion 18.23 8.28e7 7.85e3 1.00 0.00 Inf
chemo -1.82 0.16 1.97 0.35 0.003 7.60
radiation -0.50 0.61 1.98 0.80 0.01 29.50
stage 1.19 3.30 3.34 0.72 0.0005 2291.84
44
CHAPTER 3. A PANCREATIC CANCER STUDY
Table 3.5: Cause-Specific Hazard of Time from Surgery to Recurrence With Some of
the Main Effects and Interaction Terms
coef exp(coef) se(coef) p lower .95 upper .95
Recurrence-in-lung
age 0.03 1.03 0.02 0.19 0.98 1.08
gender 0.71 2.03 0.68 0.30 0.53 7.72
positive margin 2.09 8.09 0.76 0.006 1.82 35.98
lymph node 1.04 2.82 0.77 0.18 0.63 12.74
grade 0.67 1.94 0.45 0.14 0.81 4.70
vascular invasion 0.08 1.08 0.40 0.84 0.49 2.39
perneural invasion 0.36 1.43 0.69 0.60 0.37 5.48
chemo 1.56 4.77 1.49 0.30 0.26 89.13
radiation -0.90 0.41 1.09 0.41 0.05 3.46
positive margin × gender -1.91 0.15 0.90 0.03 0.03 0.86
Recurrence-in-other-sites
age -0.28 0.76 0.10 0.006 0.62 0.92
age× age 0.002 1.00 0.00 0.01 1.00 1.00
gender -3.14 0.04 1.19 0.008 0.004 0.44
positive margin 0.17 1.19 0.21 0.41 0.79 1.79
lymph node 0.37 1.44 0.28 0.19 0.84 2.48
grade -1.04 0.35 0.52 0.04 0.13 0.98
vascular invasion 0.38 1.46 0.21 0.07 0.98 2.19
perneural invasion 0.66 1.93 0.46 0.15 0.79 4.72
chemo -0.68 0.51 0.49 0.16 0.20 1.32
radiation -2.04 0.13 0.85 0.02 0.02 0.69
age × gender 0.04 1.04 0.02 0.02 1.01 1.08
radiation × grade 0.76 2.14 0.55 0.17 0.73 6.31
No-recurrence
age 0.03 1.04 0.04 0.35 0.96 1.11
gender 0.42 1.53 0.72 0.56 0.37 6.28
positive margin 0.61 1.83 0.69 0.38 0.48 7.06
lymph node 0.72 2.06 0.87 0.40 0.38 11.28
grade -1.14 0.32 0.63 0.07 0.09 1.09
vascular invasion 0.01 1.01 0.63 0.98 0.30 3.47
chemo -2.28 0.10 1.92 0.24 0.00 4.42
radiation -0.39 0.68 1.96 0.84 0.01 31.28
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Table 3.6: Cause-Specific Hazard of Time from Surgery to Death with Only Main
Effects
coef exp(coef) se(coef) p lower .95 upper .95
Recurrence-in-lung
age 0.06 1.07 0.31 0.84 0.58 1.97
age × age -0.00 1.00 0.00 0.90 0.99 1.00
gender -0.53 0.59 0.46 0.25 0.24 1.46
positive margin 0.76 2.14 0.44 0.08 0.91 5.02
lymph node 1.14 3.12 1.07 0.29 0.39 25.13
grade 0.72 2.06 0.45 0.11 0.85 4.97
vascular invasion -0.14 0.87 0.42 0.75 0.38 2.00
perneural invasion 1.12 3.05 0.83 0.18 0.60 15.48
chemo 0.55 1.74 1.37 0.69 0.12 25.74
radiation -0.14 0.87 1.03 0.89 0.12 6.58
stage 17.02 2.468e7 5.597e3 0.9976 0.00 Inf
Recurrence-in-other-sites
age -0.22 0.80 0.10 0.03 0.65 0.98
age × age 0.00 1.00 0.00 0.04 1.00 1.00
gender -0.47 0.62 0.21 0.02 0.42 0.94
positive margin 0.31 1.36 0.20 0.13 0.92 2.01
lymph node 0.24 1.28 0.33 0.46 0.67 2.42
grade -0.16 0.85 0.19 0.38 0.59 1.22
vascular invasion 0.34 1.41 0.20 0.09 0.95 2.09
perneural invasion 0.83 2.30 0.46 0.07 0.93 5.67
chemo -0.14 0.87 0.45 0.75 0.36 2.10
radiation -0.43 0.65 0.43 0.31 0.28 1.50
stage 0.06 1.06 0.54 0.91 0.37 3.05
No-recurrence
age -0.48 0.62 0.26 0.06 0.37 1.03
age × age 0.00 1.00 0.00 0.06 1.00 1.01
gender 0.06 1.07 0.66 0.92 0.29 3.90
positive margin 0.29 1.34 0.57 0.61 0.44 4.10
lymph node 1.29 3.64 0.90 0.15 0.63 21.12
grade -0.68 0.50 0.59 0.25 0.16 1.60
vascular invasion -0.73 0.48 0.57 0.20 0.16 1.46
perneural invasion 0.94 2.56 0.97 0.33 0.38 17.07
chemo -1.55 0.21 1.54 0.32 0.01 4.36
radiation 0.27 1.31 1.46 0.85 0.07 22.93
stage -0.77 0.46 1.45 0.60 0.03 7.93
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Table 3.7: Cause-Specific Hazard of Time from Surgery to Death With Some of the
Main Effects and Interaction Terms
coef exp(coef) se(coef) p lower .95 upper .95
Recurrence-in-lung
age 0.01 1.01 0.03 0.57 0.97 1.07
gender 0.50 1.65 0.69 0.47 0.42 6.45
positive margin 1.91 6.77 0.74 0.01 1.57 29.11
lymnode 1.79 5.98 1.04 0.09 0.78 46.08
grade 0.54 1.72 0.43 0.21 0.74 4.04
vascular invasion -0.15 0.86 0.41 0.71 0.38 1.92
perneural invasion 0.90 2.47 0.81 0.26 0.51 11.99
chemo 0.71 2.04 1.40 0.61 0.13 31.86
radiation -0.06 0.94 1.05 0.95 0.12 7.36
positive margin × gender -1.90 0.15 0.93 0.04 0.02 0.93
Recurrence-in-other-sites
age -0.27 0.76 0.10 0.01 0.63 0.93
age× age 0.002 1.00 0.00 0.02 1.00 1.00
gender -3.32 0.04 1.19 0.01 0.00 0.37
positive margin 0.36 1.44 0.20 0.07 0.97 2.14
lymph node 0.26 1.29 0.28 0.35 0.75 2.22
grade -0.17 0.84 0.18 0.34 0.59 1.20
vascular invasion 0.42 1.52 0.20 0.04 1.02 2.26
perneural invasion 0.83 2.28 0.46 0.07 0.93 5.62
chemo -0.20 0.82 0.46 0.66 0.33 2.02
radiation -0.49 0.61 0.43 0.25 0.26 1.42
age × gender 0.05 1.05 0.02 0.01 1.01 1.08
No-recurrence
age -0.45 0.64 0.25 0.07 0.39 1.04
age× age 0.0003 1.00 0.0003 0.07 1.00 1.01
gender 0.03 1.03 0.66 0.97 0.28 3.74
positive margin 0.31 1.37 0.57 0.58 0.45 4.17
lymph node 1.05 2.86 0.75 0.16 0.65 12.49
grade -0.61 0.54 0.58 0.29 0.18 1.67
vascular invasion -0.66 0.52 0.55 0.23 0.18 1.51
perneural invasion 0.77 2.15 0.89 0.39 0.38 12.18
chemo -1.57 0.21 1.53 0.31 0.01 4.19
rad 0.28 1.32 1.47 0.85 0.07 23.42
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Table 3.8: Cox’s Proportional Hazard with Time-Dependent Covariates
coef exp(coef) se(coef) p lower .95 upper .95
lung -0.56 0.57 0.27 0.04 0.34 0.97
other 0.60 1.82 0.19 0.002 1.25 2.64
age -0.14 0.87 0.07 0.03 0.76 0.99
age × age 0.001 1.00 0.00 0.04 1.00 1.00
gender -0.31 0.74 0.16 0.06 0.54 1.01
stage -0.08 0.93 0.33 0.82 0.49 1.77
positive margin 0.35 1.42 0.13 0.01 1.11 1.82
lymnode 0.29 1.34 0.20 0.15 0.90 2.00
grade 0.04 1.04 0.12 0.75 0.83 1.30
vascular invasion 0.03 1.04 0.12 0.78 0.81 1.32
perneural invasion 1.02 2.77 0.29 0.001 1.56 4.92
chemo 0.39 1.48 0.32 0.23 0.79 2.77
radiation -0.40 0.67 0.29 0.17 0.38 1.19
gender × other 0.28 1.33 0.26 0.27 0.80 2.20
gender × lung 0.26 1.30 0.36 0.47 0.64 2.65
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Table 3.9: Cox’s Proportional Hazard with Time-Dependent Covariates Regarding
Time of Recurrence
coef exp(coef) se(coef) p lower .95 upper .95
lung-recurrence ≤ 6 months 0.10 1.11 0.26 0.69 0.67 1.83
lung-recurrence > 6 months -0.81 0.45 0.62 0.19 0.13 1.51
other 0.67 1.95 0.14 8.79e−7 1.49 2.54
age -0.14 0.87 0.07 0.03 0.77 0.99
age × age 0.001 1.00 0.0005 0.05 1.00 1.00
gender -0.14 0.87 0.13 0.25 0.67 1.11
stage 0.05 1.05 0.32 0.88 0.56 1.99
positive margin 0.33 1.39 0.13 0.01 1.08 1.79
lymnode 0.28 1.32 0.20 0.17 0.89 1.98
grade 0.003 1.00 0.11 0.98 0.80 1.26
vascular invasion 0.02 1.02 0.12 0.88 0.80 1.30
perneural invasion 0.93 2.54 0.29 0.001 1.43 4.51
chemo 0.30 1.35 0.31 0.34 0.73 2.48




To study time from surgery to composite endpoints, recurrence or death, we an-
alyze the data under competing risks format. The unconditional CIF, though show-
ing large difference, is hard to make inference, since about 70% patients are in the
recurrence-in-other-sites subgroup. Instead, we estimate conditional CIF, condition-
ing on recurrence type. The difference still exists, especially in the first 30 months.
However, large standard deviation problem occurres in the recurrence-in-lung and no-
recurrence subgroups, which have smaller sample size. To analyze the effect of main
effects on the risk, we first use conventional Cox’s model with all the main effects as
covariates, but ignoring the recurrence type information. Then we include same main
effects in the cause-specific hazard models. The cause-specific hazard model does not
find any main effects significant when analyzing recurrence-in-lung and no-recurrence
subgroup. However, when regarding time from surgery to recurrence for recurrence-
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in-other-sites subgroup, other than the significant ones in conventional model, new
significant main effect, gender, is found. And when analyzing time from surgery to
death for the same subgroup, perneural invasion, significant in conventional model, is
not significant here. By making inference about the cause-specific model with main
effects and exploring interaction relationships between main effects, we get our final
cause-specific hazard models for three recurrence types. The cause-specific hazards
find out some covariates that influenced the risk, the significant ones. And different
cause-specific hazards have different significant covariates. However, the sample size
of two subgroups, recurrence-in-lung and no-recurrence, is very small, resulting in
the problem that some covariates have large variances. We cannot make conclusion
about how these covariates effect the risk, because of the uncertainty. To overcome
the small sample size problem in two subgroups, we, instead, utilize Cox proportional
hazard model based on the whole data set and include time-depend risk indicator
to test whether certain recurrence type effects patient’s risk. The result shows that
recurrence-in-lung does decrease patient’s risk. Further exploratory shows that di-
agnosis of recurrence in lung within 6 months after surgery increases the risk, while
diagnosis of recurrence in lung after 6 months after surgery decreases risk. However,
due to the small number of cases having recurrence in lung, more evidence is needed
to test if early recurrence in lung actually increase the risk, while only recurrence in
lung occurred after certain time decreases the risk.
The prognosis of different recurrence, particularly in lung, has not been carefully
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studied yet. Though it’s a quite a new topic, the meaning of it is profound. We
want to study the difference in survival or hazard between different recurrence, the
pattern of time to different recurrence, what characteristics may influence the pattern
of recurrence or survival of various recurrence types. Trying to answer these questions,
we use competing risks models. Though “competing risks” refers to the study of any
failure type in which there is more than one distinct type of failure, as mentioned
before, our settings here are different from conventional competing risks settings.
The patients in the study died of cancer, but different in recurrence types. We
treat different recurrence events as competing risks, and then apply competing risks
models. Our study shows that patients having had recurrence lung survives longer
than patients with recurrence in sites other than lung or not having recurrence before
death. Moreover, the period from surgery to their diagnosis of recurrence in lung is
also longer. Patients not having recurrence before death often die very quickly after
surgery. There may be genetic or psychological features in these patients, which effect
the recurrence type and also survival. Finding out these features will help doctors
make better prediction of the patients, and select appropriate treatment to increase
survival.
We study time from surgery to recurrence and time from surgery to death, but
do not study the time from recurrence to death. This will be an interesting topic.
By careful study of the time from recurrence to death, we may be able to predict the




data <- read.csv("AllDataClean.csv", head=T)
data <- data[,-c(3,4)]
cov1 <- data[,c(2:13)]
levels(cov1$Sex) <- c("F", "F", "M", "M")
levels(cov1$Stage) <- c(" ", "I", "II", "1A", "1B", "2B",
"2B", "I", "II", "III", "II", "I", "II", "III")
levels(cov1$Vascular.Invasion) <- c(" ", "N", "N", "Unknown",
"Unknown", "Y", "Y")
levels(cov1$PerineuralInvasion) <- c(" ", "N", "N", "Unknown",
"Unknown", "Y", "Y")
levels(cov1$Adjuvant.RadiationTherapy) <- c("N", "N", "Unknown",
"Unknown", "Y", "Y", "Y")
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levels(cov1$Adjuvent.Chemo) <- c("N", "N", "N", "Unknown", "Unknown",
"Y", "Y", "Y","Y")
cov1 <- data.frame(cov1, as.factor(stage), as.factor(grade))
summary(cov1)











covariate <- data.frame(age, gender, stage, marg.pos,
lymnode, grade, vas.inv, per.inv, chemo, rad)
cov <- as.matrix(covariate)
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##time to recurrence or time to death
recur <- c()
recur[data$Recur == "LungOnly"] = 1
recur[data$Recur == "LungOther" | data$Recur == "liver" |
data$Recur == "Local" | data$Recur == "Peritoneal"] = 2
recur[data$Recur == "NoRecur"] = 0
recur = as.numeric(recur)












APPENDIX A. R CODE
##Cox for T ignoring the recurrence type on main effects
cox0 <- coxph(Surv(time=T, event=T_censor) ~ age + I(age^2) + gender +
marg.pos + lymnode + grade + vas.inv + per.inv +
chemo + rad + stage, data = covariate)
summary(cox0)
##cause-specific hazard for T
##lung only
t1_censor <- T_censor






cox1.0 <- coxph(Surv(time=T, event=t1_censor) ~ age + I(age^2) + gender +
marg.pos + lymnode + grade + vas.inv + per.inv +
chemo + rad + stage, data = covariate)
summary(cox1.0)
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cox1 <- coxph(Surv(time=T, event=t1_censor) ~ age + gender +
marg.pos + lymnode + grade + vas.inv + per.inv +










cox2.0 <- coxph(Surv(time=T, event=t2_censor) ~ age + I(age^2) + gender +
marg.pos + lymnode + grade + vas.inv + per.inv +
chemo + rad + stage, data = covariate)
summary(cox2.0)
cox2 <- coxph(Surv(time=T, event=t2_censor) ~ age + I(age^2) + gender +
marg.pos + lymnode + grade + vas.inv + per.inv +
chemo + rad + I(age*gender), data = covariate)
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cox3.0 <- coxph(Surv(time=T, event=t3_censor) ~ age + I(age^2) + gender +
marg.pos + lymnode + grade + vas.inv + per.inv +
chemo + rad + stage, data = covariate)
summary(cox3)
cox3 <- coxph(Surv(time=T, event=t3_censor) ~ age + I(age^2) + gender +
marg.pos + lymnode + grade + vas.inv + per.inv +
chemo + rad, data = covariate)
summary(cox3)
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##cause-specific hazard for X
##lung only
x1_censor <- X_censor
for (i in 1:209){
if (recur[i] != 1)
x1_censor[i] = 0
}
cox1.2 <- coxph(Surv(time=X, event=x1_censor) ~ age + I(age^2) + gender +
marg.pos + lymnode + grade + vas.inv + per.inv +
chemo + rad + stage, data = covariate)
summary(cox1.2)
cox1.3 <- coxph(Surv(time=X, event=x1_censor) ~ age+ I(age^2) + gender +
marg.pos + lymnode + grade + vas.inv + per.inv +




for (i in 1:209){
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if (recur[i] != 2)
x2_censor[i] = 0
}
cox2.2 <- coxph(Surv(time=X, event=x2_censor) ~ age + I(age^2) + gender +
marg.pos + lymnode + grade + vas.inv + per.inv +
chemo + rad + stage, data = covariate)
summary(cox2.2)
cox2.3 <- coxph(Surv(time=X, event=x2_censor) ~ age + I(age^2) + gender +
marg.pos + lymnode + grade + vas.inv + per.inv +




for (i in 1:209){




APPENDIX A. R CODE
cox3.3 <- coxph(Surv(time=X, event=x3_censor) ~ age + I(age^2) + gender +
marg.pos + lymnode + grade + vas.inv + per.inv +
chemo + rad + stage, data = covariate)
summary(cox3.3)
cox3.1 <- coxph(Surv(time=X, event=x3_censor) ~ age + gender +
marg.pos + lymnode + grade + vas.inv +




##failure status (0 = censoring, 1 = no recur, 2 = lung, 3 = others)





CIF <- cuminc(T, censor)
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upper_lung <- estl + 1.96 * sqrt(varl)
lower_lung <- estl - 1.96 * sqrt(varl)
upper_other <- esto + 1.96 * sqrt(varo)
lower_other <- esto - 1.96 * sqrt(varo)
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upper_no <- est_no + 1.96 * sqrt(var_no)
lower_no <- est_no - 1.96 * sqrt(var_no)
plot(to, esto, col="red", type="s", lty=1, xlab="months", ylab="probability of death",
ylim=c(0,0.8), lwd=2)
lines(to, lower_other, lty=2, col="red", type="s")
lines(to, upper_other, lty=2, col="red", type="s")
lines(tl, estl, lty=1, col="blue", type="s", lwd=2)
lines(tl, lower_lung, lty=2, col="blue", type="s")
lines(tl, upper_lung, lty=2, col="blue", type="s")
lines(t_no, est_no, col="green", type="s", lwd=2)
lines(t_no, lower_no, lty=2, col="green", type="s")
lines(t_no, upper_no, lty=2, col="green", type="s")
legend(60, 0.55, legend=c("Recurrence in lung","Confidence interval for lung",
"Recurrence in other sites",
"Confidence interval for other sites",
"No recurrence",
"Confidence interval for no recurrence"),
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col=c("blue", "blue", "red", "red", "green", "green"), lty=c(1,2, 1, 2, 1, 2),
bty="n", cex=.75)
##doing bootstrap for recurrence on lung and recurrence in others
##function for estiamte in bootstrap
cif_est <- function(data, tl, to, t_no){
time <- data[,1]
censor <- data[,2]
cif <- cuminc(time, censor)
time_lung <- cif[2][[1]]$time ## time for lung






match1 <- match(tl, time_lung)
for(i in 1:length(tl)){
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est <- c(est1, est2, est3)
return(est)
}
cif_data <- as.matrix(data.frame(T, censor))
boot1 <- matrix(NA, nrow=52+254+54, ncol=1000)
for (i in 1:1000){
id <- sample(1:209, replace=TRUE)
sample <- cif_data[id, ]
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##95% CI for lung
boot_lung <- boot1[1:52, ]
estl_c <- estl/max(estl)
lower_lung <- apply(boot_lung, 1, function(x) quantile(x, .025))
upper_lung <- apply(boot_lung, 1, function(x) quantile(x, .975))
##95% CI for other
boot_other <- boot1[53:306, ]
esto_c <- esto/max(esto)
lower_other <- apply(boot_other, 1, function(x) quantile(x, .025))
upper_other <- apply(boot_other, 1, function(x) quantile(x, .975))
##95% CI for no
boot_no<- boot1[307:360, ]
est_no_c <- est_no/max(est_no)
lower_no <- apply(boot_no, 1, function(x) quantile(x, .025))
upper_no <- apply(boot_no, 1, function(x) quantile(x, .975))
##plot
plot(tl, estl_c, type="s", lty=1, col="blue", xlab="months",
ylab="probability of death", ylim=c(0, 1), lwd=2)
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lines(tl, lower_lung, lty=2, col="blue", type="s")
lines(tl, upper_lung, lty=2, col="blue", type="s")
lines(to, esto_c, col="red", type="s", lwd=2)
lines(to, lower_other, lty=2, col="red", type="s")
lines(to, upper_other, lty=2, col="red", type="s")
lines(t_no, est_no_c, col="green", type="s", lwd=2)
lines(t_no, lower_no, lty=2, col="green", type="s")
lines(t_no, upper_no, lty=2, col="green", type="s")
legend("bottomright", legend=c("Recurrence in lung","Confidence interval for lung",
"Recurrence in other sites",
"Confidence interval for other sites",
"No recurrence",
"Confidence interval for no recurrence"),
col=c("blue", "blue", "red", "red", "green", "green"),
lty=c(1,2, 1, 2, 1, 2), bty="n", cex=.75)
##CIF for X
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CIF2 <- cuminc(X, censor2)
print(CIF2)
plot(CIF2, lty=1, col=1:4, xlab="months")
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varo <- CIF2[3][[1]]$var
var_no <- CIF2[1][[1]]$var
upper_lung <- estl + 1.96 * sqrt(varl)
lower_lung <- estl - 1.96 * sqrt(varl)
upper_other <- esto + 1.96 * sqrt(varo)
lower_other <- esto - 1.96 * sqrt(varo)
upper_no <- est_no + 1.96 * sqrt(var_no)
lower_no <- est_no - 1.96 * sqrt(var_no)
plot(to, esto, col="red", type="s", lty=1, xlab="months",
ylab="probability of event", ylim=c(0,0.8), lwd=2)
lines(to, lower_other, lty=2, col="red", type="s")
lines(to, upper_other, lty=2, col="red", type="s")
lines(tl, estl, lty=1, col="blue", type="s", lwd=2)
lines(tl, lower_lung, lty=2, col="blue", type="s")
lines(tl, upper_lung, lty=2, col="blue", type="s")
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lines(t_no, est_no, col="green", type="s")
lines(t_no, lower_no, lty=2, col="green", type="s", lwd=2)
lines(t_no, upper_no, lty=2, col="green", type="s")
legend(60, 0.55, legend=c("Recurrence in lung","Confidence interval for lung",
"Recurrence in other sites",
"Confidence interval for other sites",
"No recurrence",
"Confidence interval for no recurrence"),
col=c("blue", "blue", "red", "red", "green", "green"),
lty=c(1,2, 1, 2, 1, 2), bty="n", cex=.75)
##doing bootstrap for recurrence on lung and recurrence in others
##function for estiamte in bootstrap
cif_est <- function(data, tl, to, t_no){
time <- data[,1]
censor <- data[,2]
cif <- cuminc(time, censor)
time_lung <- cif[2][[1]]$time ## time for lung
est_lung <- cif[2][[1]]$est ## est at time points
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boot1 <- matrix(NA, nrow=58+270+54, ncol=1000)
for (i in 1:1000){
id <- sample(1:209, replace=TRUE)
sample <- cif_data[id, ]
est <- cif_est(sample, tl=tl, to=to, t_no=t_no)
boot1[,i] <- est
}
##95% CI for lung
boot_lung <- boot1[1:58, ]
estl_c <- estl/max(estl)
lower_lung <- apply(boot_lung, 1, function(x) quantile(x, .025))
upper_lung <- apply(boot_lung, 1, function(x) quantile(x, .975))
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##95% CI for other
boot_other <- boot1[59:328, ]
esto_c <- esto/max(esto)
lower_other <- apply(boot_other, 1, function(x) quantile(x, .025))
upper_other <- apply(boot_other, 1, function(x) quantile(x, .975))
##95% CI for no
boot_no<- boot1[329:382, ]
est_no_c <- est_no/max(est_no)
lower_no <- apply(boot_no, 1, function(x) quantile(x, .025))
upper_no <- apply(boot_no, 1, function(x) quantile(x, .975))
##plot
plot(tl, estl_c, type="s", lty=1, col="blue", xlab="months",
ylab="probability of event", lwd=2)
lines(tl, lower_lung, lty=2, col="blue", type="s")
lines(tl, upper_lung, lty=2, col="blue", type="s")
lines(to, esto_c, col="red", type="s", lwd=2)
lines(to, lower_other, lty=2, col="red", type="s")
lines(to, upper_other, lty=2, col="red", type="s")
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lines(t_no, est_no_c, col="green", type="s", lwd=2)
lines(t_no, lower_no, lty=2, col="green", type="s")
lines(t_no, upper_no, lty=2, col="green", type="s")
legend("bottomright", legend=c("Recurrence in lung","Confidence interval for lung",
"Recurrence in other sites",
"Confidence interval for other sites",
"No recurrence",
"Confidence interval for no recurrence"),
col=c("blue", "blue", "red", "red", "green", "green"),
lty=c(1,2, 1, 2, 1, 2), bty="n", cex=.75)
#########################################################################################











recur[data$Recur == "LungOnly"] = 1
recur[data$Recur == "liver" | data$Recur == "Local" |
data$Recur == "Peritoneal"] = 2
recur[data$Recur == "LungOther"] =3
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##create time-dependent risk indicator
##for lung only recurrence
lung_matrix <- matrix(NA, sum(recur==1), 2)
for (i in 1:sum(recur==1)){
lung_matrix[i, 1] <- 0
lung_matrix[i, 2] <- 1
}
##for other recurrence
other_matrix <- matrix(NA, sum(recur==2), 2)
for(i in 1:sum(recur==2)){
other_matrix[i, 1] <- 0
other_matrix[i, 2] <- 1
}
##for recurrence in both lung and others
lung_matrix2 <- matrix(NA, sum(recur==3), 2)
for (i in 1:sum(recur==3)){
lung_matrix2[i, 1] <- 0
lung_matrix2[i, 2] <- 1
}
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other_matrix2 <- matrix(NA, sum(recur==3), 2)
for(i in 1:sum(recur==3)){
other_matrix2[i, 1] <- 0
other_matrix2[i, 2] <- 1
}
##for no recurrence
dataframe <- data.frame(age, gender, stage, marg.pos, lymnode,
grade, vas.inv, per.inv, chemo, rad, T_censor)
data1 <- dataframe[recur==1, ]
data2 <- dataframe[recur==2, ]
data3 <- dataframe[recur==0, ]
data4 <- dataframe[recur==3, ]
##create dataframe for recurrence-in-lung patients
sum1 <- sum(!is.na(lung_matrix)) ## count of rows
lung_group <- matrix(0, sum1, 15)
colnames(lung_group) <- c("start", "stop", "lung", "other", "censor",
"age", "gender", "stage", "marg.pos",
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"lymnode", "grade", "vas.inv", "per.inv",
"chemo", "rad")
##time to recurrence and death
lung_recur2 <- cbind(0, lung_recur, lung_death)
##create table with both time-dependent covariates and other covariates
row1<-0 #set record counter to 0
for (i in 1:nrow(data1)) { # loop over individuals
for (j in 1:2) { # loop over time points
if (is.na(lung_matrix[i,j])) next #
else {
row1 <- row1 + 1 # increment row counter
start <- lung_recur2[i,j] # start time
stop <- lung_recur2[i,j+1] # stop time
lung <- lung_matrix[i,j] ##time-dependent risk indicator
other <- 0
censor <- if (stop == lung_death[i] && data1[i,11] == 0) 0 else 1
## censoring indicator
#construct result
lung_group[row1,] <- c(start, stop, lung, other, censor,
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sum2 <- sum(!is.na(other_matrix)) ## count of rows
other_group <- matrix(0, sum2, 15)
colnames(other_group) <- c("start", "stop", "lung", "other", "censor",
"age", "gender", "stage", "marg.pos",
"lymnode", "grade", "vas.inv", "per.inv",
"chemo", "rad")
other_recur2 <- cbind(0, other_recur, other_death)
row2<-0 #set record counter to 0
for (i in 1:nrow(data2)) { # loop over individuals
for (j in 1:2) { # loop over time points
row2 <- row2 + 1 # increment row counter
start <- other_recur2[i,j] # start time
stop <- other_recur2[i,j+1] # stop time
lung <- 0
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other <- other_matrix[i,j]
censor <- if (stop == other_death[i] && data2[i,11] == 0) 0 else 1
## censoring indicator
#construct result




both_group <- matrix(0, 2*nrow(data4), 15)
colnames(both_group) <- c("start", "stop", "lung", "other", "censor",
"age", "gender", "stage", "marg.pos",
"lymnode", "grade", "vas.inv", "per.inv",
"chemo", "rad")
both_recur2 <- cbind(0, both_recur, both_death)
row4 <- 0
for (i in 1:nrow(data4)) { # loop over individuals
for (j in 1:2) { # loop over time points
row4 <- row4 + 1 # increment row counter
start <- both_recur2[i,j] # start time
82
APPENDIX A. R CODE
stop <- both_recur2[i,j+1] # stop time
lung <- lung_matrix2[i, j]
other <- other_matrix2[i, j]
censor <- if (stop == both_death[i] && data4[i,11] == 0) 0 else 1
## censoring indicator
#construct result




no_group <- matrix(0, nrow(data3), 15)
colnames(no_group) <- c("start", "stop", "lung", "other", "censor",
"age", "gender", "stage", "marg.pos", "lymnode",
"grade", "vas.inv", "per.inv", "chemo", "rad")
row3<-0 #set record counter to 0
no_recur2 <- c(0, no_recur)
for (i in 1:nrow(data3)) { # loop over individuals
row3 <- row3 + 1 # increment row counter
start <- no_recur2[1] # start time
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stop <- no_recur2[2] # stop time
lung <- 0
other <- 0
censor <- if (stop == no_recur[i] && data3[i,11] == 0) 0 else 1
## censoring indicator
#cinstruct result
no_group[row3,] <- c(start, stop, lung, other, censor,
unlist(data3[i, c(1:10)]))
}
cancer <- as.data.frame(rbind(lung_group, other_group,
both_group, no_group))
cox <- coxph(Surv(start, stop, censor) ~ lung + other + age +
I(age*age) + gender + stage + marg.pos +
lymnode + grade + vas.inv + per.inv + chemo + rad +
I(gender*other)+I(gender*lung), data = cancer)
summary(cox)
##with indicator whether the recurrence time is within certain time
##set the cut point for recurrence
cut <- 6
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##create time-dependent risk indicator
##for lung only recurrence
lung_matrix <- matrix(NA, sum(recur==1), 2)
for (i in 1:sum(recur==1)){
lung_matrix[i, 1] <- 0
lung_matrix[i, 2] <- 1
}
##for other recurrence
other_matrix <- matrix(NA, sum(recur==2), 2)
for(i in 1:sum(recur==2)){
other_matrix[i, 1] <- 0
other_matrix[i, 2] <- 1
}
##for recurrence in both lung and others
lung_matrix2 <- matrix(NA, sum(recur==3), 2)
for (i in 1:sum(recur==3)){
lung_matrix2[i, 1] <- 0
lung_matrix2[i, 2] <- 1
}
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other_matrix2 <- matrix(NA, sum(recur==3), 2)
for(i in 1:sum(recur==3)){
other_matrix2[i, 1] <- 0
other_matrix2[i, 2] <- 1
}
##for no recurrence
dataframe <- data.frame(age, gender, stage, marg.pos,
lymnode, grade, vas.inv, per.inv, chemo, rad, T_censor)
data1 <- dataframe[recur==1, ]
data2 <- dataframe[recur==2, ]
data3 <- dataframe[recur==0, ]
data4 <- dataframe[recur==3, ]
##create dataframe for recurrence-in-lung patients
sum1 <- sum(!is.na(lung_matrix)) ## count of rows
lung_group <- matrix(0, sum1, 17)
colnames(lung_group) <- c("start", "stop", "lung =< 6","lung > 6",
"other<=6","other>6", "censor", "age", "gender",
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"stage", "marg.pos", "lymnode", "grade",
"vas.inv", "per.inv", "chemo", "rad")
##time to recurrence and death
lung_recur2 <- cbind(0, lung_recur, lung_death)
lung_id1 <- (lung_recur > cut)
lung_id2 <- (lung_recur <= cut)
##create table with both time-dependent covariates and other covariates
row1<-0 #set record counter to 0
for (i in 1:nrow(data1)) { # loop over individuals
for (j in 1:2) { # loop over time points
if (is.na(lung_matrix[i,j])) next #
else {
row1 <- row1 + 1 # increment row counter
start <- lung_recur2[i,j] # start time
stop <- lung_recur2[i,j+1] # stop time
lung1 <- lung_matrix[i,j] * lung_id1[i]
##time-dependent risk indicator
lung2 <- lung_matrix[i,j] * lung_id2[i]
other1 <- 0
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other2 <- 0
censor <- if (stop == lung_death[i] && data1[i,11] == 0) 0 else 1
## censoring indicator
#construct result
lung_group[row1,] <- c(start, stop, lung1, lung2, other1,




sum2 <- sum(!is.na(other_matrix)) ## count of rows
other_group <- matrix(0, sum2, 17)
colnames(other_group) <- c("start", "stop", "lung =< 6","lung > 6",
"other<=6","other>6", "censor", "age", "gender",
"stage", "marg.pos", "lymnode", "grade",
"vas.inv", "per.inv", "chemo", "rad")
other_recur2 <- cbind(0, other_recur, other_death)
other_id1 <- (other_recur <= cut)
other_id2 <- (other_recur > cut)
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row2<-0 #set record counter to 0
for (i in 1:nrow(data2)) { # loop over individuals
for (j in 1:2) { # loop over time points
row2 <- row2 + 1 # increment row counter
start <- other_recur2[i,j] # start time
stop <- other_recur2[i,j+1] # stop time
lung1 <- 0
lung2 <- 0
other1 <- other_matrix[i,j] * other_id1[i]
other2 <- other_matrix[i,j] * other_id2[i]
censor <- if (stop == other_death[i] && data2[i,11] == 0) 0 else 1
## censoring indicator
#construct result




both_group <- matrix(0, 2*nrow(data4), 17)
colnames(both_group) <- c("start", "stop", "lung =< 6","lung > 6",
"other<=6","other>6", "censor", "age", "gender",
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"stage", "marg.pos", "lymnode", "grade",
"vas.inv", "per.inv", "chemo", "rad")
both_recur2 <- cbind(0, both_recur, both_death)
both_id1 <- (both_recur <= cut)
both_id2 <- (both_recur > cut)
row4 <- 0
for (i in 1:nrow(data4)) { # loop over individuals
for (j in 1:2) { # loop over time points
row4 <- row4 + 1 # increment row counter
start <- both_recur2[i,j] # start time
stop <- both_recur2[i,j+1] # stop time
lung1 <- 0
lung2 <- 0
other1 <- other_matrix2[i, j] * both_id1[i]
other2 <- other_matrix2[i, j] * both_id2[i]
censor <- if (stop == both_death[i] && data4[i,11] == 0) 0 else 1
## censoring indicator
#construct result
both_group[row4,] <- c(start, stop, lung1, lung2, other1, other2,
censor, unlist(data4[i, c(1:10)]))
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}
}
no_group <- matrix(0, nrow(data3), 17)
colnames(no_group) <- c("start", "stop", "lung =< 6","lung > 6",
"other<=6","other>6", "censor", "age", "gender",
"stage", "marg.pos", "lymnode", "grade",
"vas.inv", "per.inv", "chemo", "rad")
row3<-0 #set record counter to 0
no_recur2 <- c(0, no_recur)
for (i in 1:nrow(data3)) { # loop over individuals
row3 <- row3 + 1 # increment row counter
start <- no_recur2[1] # start time





censor <- if (stop == no_recur[i] && data3[i,11] == 0) 0 else 1
## censoring indicator
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#construct result
no_group[row3,] <- c(start, stop, lung1, lung2, other1, other2,
censor, unlist(data3[i, c(1:10)]))
}
cancer <- as.data.frame(rbind(lung_group, other_group,
both_group, no_group))
colnames(cancer) <- c("start", "stop", "lung1","lung2", "other1","other2",
"censor", "age", "gender",
"stage", "marg.pos", "lymnode", "grade",
"vas.inv", "per.inv", "chemo", "rad")
cox <- coxph(Surv(start, stop, censor) ~ lung1 + lung2 + other1
+ other2 + age + I(age*age) + gender + stage +
marg.pos + lymnode + grade + vas.inv + per.inv
+ chemo + rad, data = cancer)
summary(cox)
##include only the recurrence cut for lung recurrence
##set the cut point for recurrence
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cut <- 6
##create time-dependent risk indicator
##for lung only recurrence
lung_matrix <- matrix(NA, sum(recur==1), 2)
for (i in 1:sum(recur==1)){
lung_matrix[i, 1] <- 0
lung_matrix[i, 2] <- 1
}
##for other recurrence
other_matrix <- matrix(NA, sum(recur==2), 2)
for(i in 1:sum(recur==2)){
other_matrix[i, 1] <- 0
other_matrix[i, 2] <- 1
}
##for recurrence in both lung and others
lung_matrix2 <- matrix(NA, sum(recur==3), 2)
for (i in 1:sum(recur==3)){
lung_matrix2[i, 1] <- 0
lung_matrix2[i, 2] <- 1
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}
other_matrix2 <- matrix(NA, sum(recur==3), 2)
for(i in 1:sum(recur==3)){
other_matrix2[i, 1] <- 0
other_matrix2[i, 2] <- 1
}
##for no recurrence
dataframe <- data.frame(age, gender, stage, marg.pos, lymnode,
grade, vas.inv, per.inv, chemo, rad, T_censor)
data1 <- dataframe[recur==1, ]
data2 <- dataframe[recur==2, ]
data3 <- dataframe[recur==0, ]
data4 <- dataframe[recur==3, ]
##create dataframe for recurrence-in-lung patients
sum1 <- sum(!is.na(lung_matrix)) ## count of rows
lung_group <- matrix(0, sum1, 16)
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colnames(lung_group) <- c("start", "stop", "lung =< 6","lung > 6",
"other", "censor", "age", "gender",
"stage", "marg.pos", "lymnode", "grade",
"vas.inv", "per.inv", "chemo", "rad")
##time to recurrence and death
lung_recur2 <- cbind(0, lung_recur, lung_death)
lung_id1 <- (lung_recur > cut)
lung_id2 <- (lung_recur <= cut)
##create table with both time-dependent covariates and other covariates
row1<-0 #set record counter to 0
for (i in 1:nrow(data1)) { # loop over individuals
for (j in 1:2) { # loop over time points
if (is.na(lung_matrix[i,j])) next #
else {
row1 <- row1 + 1 # increment row counter
start <- lung_recur2[i,j] # start time
stop <- lung_recur2[i,j+1] # stop time
lung1 <- lung_matrix[i,j] * lung_id1[i]
##time-dependent risk indicator
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lung2 <- lung_matrix[i,j] * lung_id2[i]
other <- 0
censor <- if (stop == lung_death[i] && data1[i,11] == 0) 0 else 1
## censoring indicator
#construct result





sum2 <- sum(!is.na(other_matrix)) ## count of rows
other_group <- matrix(0, sum2, 16)
colnames(other_group) <- c("start", "stop", "lung =< 6","lung > 6",
"other", "censor", "age", "gender",
"stage", "marg.pos", "lymnode", "grade",
"vas.inv", "per.inv", "chemo", "rad")
other_recur2 <- cbind(0, other_recur, other_death)
other_id1 <- (other_recur <= cut)
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other_id2 <- (other_recur > cut)
row2<-0 #set record counter to 0
for (i in 1:nrow(data2)) { # loop over individuals
for (j in 1:2) { # loop over time points
row2 <- row2 + 1 # increment row counter
start <- other_recur2[i,j] # start time




censor <- if (stop == other_death[i] && data2[i,11] == 0) 0 else 1
## censoring indicator
#construct result




both_group <- matrix(0, 2*nrow(data4), 16)
colnames(both_group) <- c("start", "stop", "lung =< 6","lung > 6",
"other", "censor", "age", "gender",
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"stage", "marg.pos", "lymnode", "grade",
"vas.inv", "per.inv", "chemo", "rad")
both_recur2 <- cbind(0, both_recur, both_death)
row4 <- 0
for (i in 1:nrow(data4)) { # loop over individuals
for (j in 1:2) { # loop over time points
row4 <- row4 + 1 # increment row counter
start <- both_recur2[i,j] # start time
stop <- both_recur2[i,j+1] # stop time
lung1 <- 0
lung2 <- 0
other <- other_matrix2[i, j]
censor <- if (stop == both_death[i] && data4[i,11] == 0) 0 else 1
## censoring indicator
#construct result
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no_group <- matrix(0, nrow(data3), 16)
colnames(no_group) <- c("start", "stop", "lung =< 6","lung > 6",
"other", "censor", "age", "gender",
"stage", "marg.pos", "lymnode", "grade",
"vas.inv", "per.inv", "chemo", "rad")
row3<-0 #set record counter to 0
no_recur2 <- c(0, no_recur)
for (i in 1:nrow(data3)) { # loop over individuals
row3 <- row3 + 1 # increment row counter
start <- no_recur2[1] # start time




censor <- if (stop == no_recur[i] && data3[i,11] == 0) 0 else 1
## censoring indicator
#construct result
no_group[row3,] <- c(start, stop, lung1, lung2, other,
censor, unlist(data3[i, c(1:10)]))
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}
cancer <- as.data.frame(rbind(lung_group, other_group,
both_group, no_group))
colnames(cancer) <- c("start", "stop", "lung1","lung2",
"other", "censor", "age", "gender",
"stage", "marg.pos", "lymnode", "grade",
"vas.inv", "per.inv", "chemo", "rad")
cox <- coxph(Surv(start, stop, censor) ~ lung1 + lung2 + other +
age + I(age*age) + gender + stage +
marg.pos + lymnode + grade + vas.inv + per.inv +
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